Company: STAA
Filing Date: 2025-09-26
Form Type: DFAN14A
Source: 0001213900-25-092390
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DFAN14A
Chunk 1
---
 special meeting of stockholders
scheduled for October 23, 2025 (including any adjournments, postponements, reschedulings or continuations thereof, the “Special
Meeting”). The Participants have filed a definitive proxy statement on Schedule 14A (the “Definitive Proxy Statement”)
and accompanying GREEN Proxy Card to be used in connection with any such solicitation of proxies from the Company’s
stockholders for the Special Meeting. STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE SEC BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SPECIAL MEETING AND additional information relating to the Participants and their direct or indirect interests, by security holdings or otherwise. The Definitive
Proxy Statement and accompanying GREEN Proxy Card have been furnished to some or all of the Company’s stockholders
and will be, along with other relevant documents, available at no charge on the SEC’s website at https://www.sec.gov/.

Information about the Participants and a description
of their direct or indirect interests, by security holdings or otherwise, is contained in the Definitive Proxy Statement filed by the
Participants with the SEC on September 24, 2025.

Exhibit 1

Exhibit 2

<div align='center'>STAA/ALC:
Former CEO outlines case for shareholders to reject deal at current price

By Diane Alter</div>

Given proxy advisors’ influence over institutional
votes, the goals of David Bailey, former STAAR CEO, and Pascal Aeschlimann, who once led the company’s expansion in Asia, are clear:
to frame STAAR’s narrative so Institutional Shareholder Services (ISS) and Glass Lewis see a rejection of a lowball offer as consistent
with their own policy precedents.

When Alcon first approached STAAR Surgical in 2024, negotiations
centered on a price north of $50 per share, plus an additional $7 kicker based on performance. One year later, shareholders are being
asked to accept an offer that is barely half that amount.

To Bailey and
Aeschlimann, the math makes no sense. Both have argued that STAAR’s management misplayed its hand, handing Alcon an outsized
advantage and a “significant gift”.

Bailey’s